Tweets by SSO 2024 Annual Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Recorded for On-Demand Viewing

Type here to filter the list

Thursday, Mar 21st
10:00am - 10:30am ET
Melanoma Poster Presentations 1
Location: C110
Poster Session Moderator: Joal D. Beane, MD – The Ohio State University
Poster Session Moderator: Camille Stewart, MD, FSSO, FACS (she/her/hers) – CommonSpirit Health, St. Anthony Hospital
Melanomanon-CMEPosters
Thursday, Mar 21st
10:01am - 10:07am ET
P38: Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates
Location: C110
Oral Poster Presenter: Aaron J. Dinerman, MD – Surgery Branch, National Cancer Institute
Submitter: Aaron J. Dinerman, MD – Surgery Branch, National Cancer Institute
Author: Aaron J. Dinerman, MD – Surgery Branch, National Cancer Institute
Author: Alexandra M. Gustafson, MD – Surgery Branch, National Cancer Institute
Author: Ali T. Elsaadi, MD – Texas Tech University Health Sciences Center
Author: Donald White, MS – Surgery Branch, National Cancer Institute
Author: David S. Schrump, MD, MBA, FACS – Thoracic Surgery Branch, National Cancer Institute
Author: Chuong D. Hoang, MD, FACS – Thoracic Surgery Branch, National Cancer Institute
Author: Jonathan M. Hernandez, MD – Surgical Oncology Program, National Cancer Institute
Author: Mei Li Kwong, MD – Surgery Branch, National Cancer Institute
Author: James C. Yang, MD – Surgery Branch, National Cancer Institute
Author: Stephanie L. Goff, MD – Surgery Branch, National Cancer Institute
Author: Steven A. Rosenberg, MD, PhD – Surgery Branch, National Cancer Institute
Author: Nicholas D. Klemen, MD – Surgery Branch, National Cancer Institute
Melanoma
Thursday, Mar 21st
10:07am - 10:13am ET
P39: Hyperthermic Isolated Limb Perfusion in the Era of Effective Systemic Immunotherapy
Location: C110
Oral Poster Presenter: Daniel K. Knewitz, MD – Mayo Clinic
Submitter: Daniel K. Knewitz, MD – Mayo Clinic
Author: Daniel K. Knewitz, MD – Mayo Clinic
Author: Jennifer Racz, M.D. – University of Wisconsin
Author: Richard Gray, M.D. – Mayo Clinic
Author: Lisa Kottschade, APRN, C.N.P – Mayo Clinic
Author: William Harmsen, M.A. – Mayo Clinic
Author: Svetomir Markovic, M.D., Ph.D. – Mayo Clinic
Author: James W. Jakub, M.D. – Mayo Clinic Florida
Melanoma
Thursday, Mar 21st
10:13am - 10:19am ET
P40: Frequency and Predictors of Metastatic Disease in Sentinel Node Positive Malignant Melanoma
Location: C110
Oral Poster Presenter: Christina S. Boutros, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Submitter: Christina S. Boutros, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Author: Christina S. Boutros, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Author: Hanna Kakish, MD – University Hospitals Cleveland Medical Center
Author: Alexander W. Loftus, MD – University Hospitals Cleveland Medical Center
Author: Luke D. Rothermel, MD MPH – University Hospitals Cleveland Medical Center
Author: Richard S. Hoehn, MD – University Hospitals Cleveland Medical Center
Melanoma
Thursday, Mar 21st
10:19am - 10:25am ET
P41: Whole Transcriptome Profiling of Patients with In Transit Melanoma
Location: C110
Oral Poster Presenter: Kristen E. Rhodin, MD, MHS – Duke University Medical Center
Submitter: Kristen E. Rhodin, MD, MHS – Duke University Medical Center
Author: Shayna Hollander, BA – Duke University Medical Center
Author: Douglas S. Tyler, MD – University of Texas Medical Branch
Author: Georgia M. Beasley, MD MHS (she/her/hers) – Duke University Medical Center
Author: Smita Nair, PhD – Duke University Medical Center
Author: Matthew K. Iyer, MD/PhD (he/him/his) – University of Michigan
Melanoma
Thursday, Mar 21st
10:35am - 11:20am ET
Melanoma Great Debate: Targeted versus Complete Nodal Dissection following Neoadjuvant Therapy for Melanoma: Is it Time to Push Forward or Hold off on Continued De-escalation of Surgery?
Location: C101
Moderator: Marc D. Moncrieff, MD FRCS(Plast.) – Norfolk & Norwich University Hospital
MelanomaCME
Thursday, Mar 21st
1:55pm - 3:25pm ET
Melanoma Parallel Session
Location: C102
Moderator: Jeffrey E. Gershenwald, MD (he/him/his) – Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Moderator: Elizabeth J. Lilley, MD, MPH (she/her/hers) – Brigham and Women's Hospital
MelanomaCMEOral Abstracts
Thursday, Mar 21st
1:57pm - 2:07pm ET
60: Management and outcomes of patients with recurrence of cutaneous melanoma during or after completion of adjuvant immunotherapy: a multicenter study
Location: C102
Abstract Presenter: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Submitter: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Author: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Author: Hannah L. Kalvin, MSPH – Memorial Sloan Kettering Cancer Center
Author: Mackenzie L. Shindorf, MD – University of Louisville
Author: Kristen E. Rhodin, MD, MHS – Duke University Medical Center
Author: Murtuza Saifuddin, MD – Sunnybrook Health Sciences Centre
Author: Christine Tran, BA – UVA
Author: Gabrielle Schwartzman, MD – UVA
Author: Cimarron E. Sharon, MD – University of Pennsylvania
Author: Aleigha Lawless, BA – Massachusetts General Hospital
Author: Giorgos Karakousis, MD – Hospital of the University of Pennsylvania
Author: Elizabeth Gaughan, MD – UVA
Author: Craig Slingluff, MD – UVA
Author: Frances C. Wright, MD MEd – Sunnybrook Health Sciences Centre
Author: Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Author: Katherine Panageas, DrPH – MSKCC
Author: Georgia M. Beasley, MD MHS (she/her/hers) – Duke University Medical Center
Author: Michael E. Egger, MD, MPH – University of Louisville
Author: Edmund Bartlett, MD – MSKCC
Melanoma
Thursday, Mar 21st
2:07pm - 2:17pm ET
61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.
Location: C102
Author: Liselotte Tas, MD (she/her/hers) – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Submitter: Liselotte Tas, MD (she/her/hers) – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Author: Marie B. Weitemeyer, MD – Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Maartje W. Rohaan, MD – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Author: Troels H. Borch, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte,Herlev, Denmark
Author: Alexander C.J van Akkooi, MD, PhD (he/him/his) – Melanoma Institute Australia / University of Sydney, Faculty of Medicine and Health / Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology
Author: Michel W.J.M. Wouters, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Koen J. Hartemink, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Yvonne Schrage, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Anke Kuijpers, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Maaike Van Zon, BSc – Netherlands Cancer Institute, Biotherapeutics Unit, Amsterdam, The Netherlands
Author: Inge jedema, PhD – Division of Molecular Oncology and Immunology, Netherlands Cancer Institute
Author: Cynthia Nijenhuis, PhD – Netherlands Cancer Institute, Biotherapeutics Unit, Amsterdam, The Netherlands
Author: Bastiaan Nuijen, PhD – Netherlands Cancer Institute, Division of Pharmacy and Pharmacology, Amsterdam, The Netherlands
Author: Sebastian Klobuch, MD – Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
Author: Ferry Lalezari, MD – Netherlands Cancer Institute, Division of Radiology, Amsterdam, The Netherlands
Author: Marco Donia, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Inge Marie Svane, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: John B.A.G. Haanen, MD, PhD – Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
Author: Lisbet R. Holmich, MD, DMSc – Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Winan J. van Houdt, MD, PhD, MS – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Abstract Presenter: Winan J. van Houdt, MD, PhD, MS – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Melanoma
Thursday, Mar 21st
2:17pm - 2:27pm ET
62: Prospective validation of the integrated 31-gene expression profile test for cutaneous melanoma to select patients who may consider foregoing sentinel lymph node biopsy
Location: C102
Abstract Presenter: J. Michael Guenther, MD – St Elizabeth Physicians
Author: Andrew Ward, PhD – Division of Surgical Oncology, University of Tennessee Medical Center
Author: Brian Martin, PhD – Castle Biosciences, Inc.
Author: Rohit Sharma, MD, FACS – Marshfield Medical Center
Author: Maki Yamamoto, MD – School of Medicine, University of California-Irvine
Melanoma
Thursday, Mar 21st
2:27pm - 2:37pm ET
63: An Externally Validated Online Tool To Calculate Personalized Probabilities Of Recurrence-Free And Overall-Survival In Stage II Melanoma Patients.
Location: C102
Abstract Presenter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Submitter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Isabel Li, n/a – University of Sydney
Author: Mary-Ann El Sharouni, MD PhD – University of Utrecht
Author: Julie Simon, MD – MD Anderson Cancer Center
Author: Aikaterini Dedeilia, MD (she/her/hers) – Massachusetts General Hospital
Author: Robyn Saw, MBBS, FRACS, MS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Andrew Spillane, MBBS, MD, FRACS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Kerwin Shannon, MBBS, FRACS – Melanoma Institute Australia
Author: Jonathan R. Stretch, DPhil FRACS – Melanoma Institute Australia
Author: Ryan J. Sullivan, MD – Massachusetts General Hospital
Author: Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Author: Jeffrey E. Gershenwald, MD (he/him/his) – Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Author: Paul van Diest, MD – University of Utrecht
Author: Richard Scolyer, BMedSci MBBS MD FRCPA FRCPath(UK) FAHMS – Melanoma Institute Australia
Author: Georgina V. Long, MBBS PhD – Melanoma Institute Australia
Author: John Thompson, MBBS, MD, DSc, FRACS, FACS (Hon), FAHMS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Serigne N. Lo, PhD – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Melanoma
Thursday, Mar 21st
2:37pm - 2:47pm ET
64: Hepatic and Overall Progression-Free Survival after Percutaneous Hepatic Perfusion as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma
Location: C102
Abstract Presenter: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Submitter: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Michelle M. Dugan, MD – Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL
Author: Shaliz Aflatooni, BS (she/her/hers) – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Aleena Boby, B.A. (she/her/hers) – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Danielle K. DePalo, MD (she/her/hers) – Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA
Author: Jose Laborde, PhD – Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa FL
Author: Jonathan S. Zager, MD – H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Thursday, Mar 21st
2:47pm - 2:57pm ET
65: Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Location: C102
Abstract Presenter: Amanda R. Kirane, MD, PhD (she/her/hers) – Stanford University
Submitter: David Lee, B.A. (he/him/his) – Loma Linda University School of Medicine
Author: M. Usman Ahmad, MD (he/him/his) – Stanford University
Author: Saurabh Sharma, Ph.D. – Stanford University
Author: Mamatha Serasanambati, Ph.D. – Stanford University
Author: Michael C. Lowe, MD, MA – Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University
Author: Christopher Applebee, Ph.D. – University of Bath
Author: Elena Safrygina, Ph.D. – University of Bath
Author: Susan Swetter, M.D. – Stanford University
Author: Sunil Reddy, M.D. – Stanford University
Author: Alison Warner, M.D., Ph.D. – Stanford University
Author: Pauline Funchain, M.D. – Stanford University
Author: Jennifer Wang, M.D. – Stanford University
Author: Ronald Levy, M.D. – Stanford University
Author: Banafshe Larijani, n/a – University of Bath
Author: Emanual Maverakis, M.D. – UC Davis
Melanoma
Thursday, Mar 21st
2:57pm - 3:07pm ET
66: Improved Survival with Sentinel Node Biopsy - An Emulated Randomized Controlled Trial
Location: C102
Abstract Presenter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Submitter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Raphael P. Feser, n/a – Melanoma Institute Australia
Author: Nurudeen A. Adegoke, n/a – Melanoma Institute Australia
Author: Richard Scolyer, BMedSci MBBS MD FRCPA FRCPath(UK) FAHMS – Melanoma Institute Australia
Author: John Thompson, MBBS, MD, DSc, FRACS, FACS (Hon), FAHMS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Serigne N. Lo, PhD – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Melanoma
Thursday, Mar 21st
3:07pm - 3:17pm ET
67: The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis
Location: C102
Abstract Presenter: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Submitter: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Author: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Author: Daphne Remulla, MD – Cleveland Clinic
Author: Chase J. Wehrle, MD – Cleveland Clinic
Author: Kimberly P. Woo, MD – Cleveland Clinic
Author: Daniel Joyce, MBBCh – Cleveland Clinic
Author: Samer A. naffouje, MD – Cleveland Clinic Foundation
Melanoma
Thursday, Mar 21st
4:00pm - 4:30pm ET
Hot Topics in Melanoma
Location: SSO HUB: Pan Tumor Zone
HUB Moderator: Michael C. Lowe, MD, MA – Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University
Melanomanon-CMEHUB
Thursday, Mar 21st
7:00pm - 9:00pm ET
PeerView Melanoma Symposium
Location: C110
Presenter: Jennifer Wargo – The University of Texas MD Anderson Cancer Center
Presenter: Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Presenter: Hussein A. Tawbi, MD, PhD – The University of Texas MD Anderson Cancer Center
MelanomaCME
Friday, Mar 22nd
11:00am - 11:30am ET
Melanoma Poster Presentations 2
Location: C110
Poster Session Moderator: Sonia Cohen, MD, PhD – Massachusetts General Hospital
Poster Session Moderator: Franz Smith, MD MAcM MAS FACS (he/him/his) – Cooperman Barnabas Medical Center RWJ Barabas Health
Melanomanon-CMEPosters
Friday, Mar 22nd
11:01am - 11:07am ET
P42: Utilization of the Melanoma Institute of Australia's Sentinel Lymph Node Metastasis Risk Calculator Reduces Sentinel Lymph Node Biopsy Utilization in T1 Cutaneous Melanoma
Location: C110
Oral Poster Presenter: Jason M. Aubrey, MD – Corewell Health - Michigan State University
Submitter: Jason M. Aubrey, MD – Corewell Health - Michigan State University
Author: Jason M. Aubrey, MD – Corewell Health - Michigan State University
Author: Hannah R. Liefeld, MD – Corewell Health - Michigan State University
Author: Hordur M. Kolbeinsson, MD – Corewell Health - Michigan State University
Author: Allison Swider, B.S. – Michigan State University College of Human Medicine
Author: Cade A. Cantu, B.S. – Central Michigan College of Medicine
Author: Madi Mangione, B.S. – Michigan State University College of Human Medicine
Author: Gerald P. Wright, MD – Corewell Health - Michigan State University
Melanoma
Friday, Mar 22nd
11:07am - 11:13am ET
P43: Innovation in Collaborating and Funding an International Cancer Clinical Trial
Location: C110
Oral Poster Presenter: Joshua M.V Mammen, MD PhD – University of Nebraska Medical Center
Submitter: Joshua M.V Mammen, MD PhD – University of Nebraska Medical Center
Author: Joshua M.V Mammen, MD PhD – University of Nebraska Medical Center
Author: Michael A. Henderson, n/a – Division of Cancer Surgery, Peter MacCallum Cancer Centre
Author: Frances C. Wright, MD MEd – Sunnybrook Health Sciences Centre
Author: Marc D. Moncrieff, MD FRCS(Plast.) – Norfolk & Norwich University Hospital
Author: Andrew Spillane, MBBS, MD, FRACS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: David Gyorki, n/a – Division of Cancer Surgery, Peter MacCallum Cancer Centre
Author: Robyn Saw, MBBS, FRACS, MS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Roger Olofsson Bagge, MD, PhD – Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Author: Janet Dancey, MD – Queen's University
Author: Katja Loewe, MSc – Melanoma and Skin Cancer Trials Ltd
Author: John Thompson, MBBS, MD, DSc, FRACS, FACS (Hon), FAHMS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Melanoma
Friday, Mar 22nd
11:13am - 11:19am ET
P44: Social Determinants of Health Predict Lower Receipt of Systemic Treatment and Worse Survival in Patients with Metastatic Melanoma
Location: C110
Oral Poster Presenter: Hanna Kakish, MD – University Hospitals Cleveland Medical Center
Submitter: Hanna Kakish, MD – University Hospitals Cleveland Medical Center
Author: Hanna Kakish, MD – University Hospitals Cleveland Medical Center
Author: Hailey Seibert, BA – Case Western Reserve University School of Medicine, Cleveland, OH
Author: Maira Bhatty, MS – Case Western Reserve University School of Medicine, Cleveland, OH
Author: Adam Wade, BA – Case Western Reserve University School of Medicine, Cleveland, OH
Author: Henry Herrera, BA – Case Western Reserve University School of Medicine, Cleveland, OH
Author: Richard S. Hoehn, MD – University Hospitals Cleveland Medical Center
Author: Luke D. Rothermel, MD MPH – University Hospitals Cleveland Medical Center
Melanoma
Friday, Mar 22nd
11:19am - 11:25am ET
P45: Head & neck primary cutaneous melanoma patients stratified by CP-GEP (Merlin Assay): risk of nodal metastasis and long-term survival outcome
Location: C110
Oral Poster Presenter: Tina J. Hieken, MD – Mayo Clinic
Author: Mark R. Pittelkow, M.D. – Mayo Clinic
Author: Wesley Yu, M.D. – Oregon Health & Science University
Author: Tina J. Hieken, MD – Mayo Clinic
Author: Renske Wever, BSc – SkylineDx BV
Author: Felicia Tjien-Fooh, MSc – SkylineDx BV
Author: Jvalini Dwarkasing, PhD – SkylineDx BV
Author: Alexander Meves, MD; MBA – Mayo Clinic
Melanoma
Friday, Mar 22nd
1:50pm - 2:02pm ET
58: Uveal Melanoma Immunogenomics Predict Immunotherapy Resistance and Susceptibility
Location: Georgia Ballroom
Abstract Presenter: Shravan Leonard-Murali, MD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA Department of Surgery, Allegheny Health Network, Pittsburgh, PA, USA
Submitter: Shravan Leonard-Murali, MD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA Department of Surgery, Allegheny Health Network, Pittsburgh, PA, USA
Author: Shravan Leonard-Murali, MD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA Department of Surgery, Allegheny Health Network, Pittsburgh, PA, USA
Author: Chetana Bhaskarla, PhD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Ghanshyam Yadav, PhD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Sudeep Maurya, PhD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Chenna Galiveti, PhD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Joshua Tobin, BS – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Rachel Kann, BS – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Eishan Ashwat, BS – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Patrick Murphy, PhD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Anish Chakka, PhD – Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Vishal Soman, BS – Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Paul Cantalupo, PhD – Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Xinming Zhuo, PhD – UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Gopi Vyas, MS – UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Dara Kozak, BS – UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Lindsey Kelly, PhD – UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Ed Smith, MBA – UPMC Genome Center, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Uma Chandran, PhD – Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Yen-Michael Hsu, MD, PhD – UPMC Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, Pittsburgh, PA, USA.
Author: Udai Kammula, MD – Solid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Melanoma
Friday, Mar 22nd
2:02pm - 2:14pm ET
59: Surgical considerations for resecting the index lymph node after neo-adjuvant checkpoint inhibitors: lessons learned from the PRADO trial
Location: Georgia Ballroom
Abstract Presenter: Winan J. van Houdt, MD, PhD, MS – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Anke Kuijpers, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Irene Reijers, MD – Netherlands Cancer Institute - Antoni van Leeuwenhoek
Author: Dirk Grunhagen, MD PhD – Erasmus MC Rotterdam
Author: Yvonne Schrage, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Michel W.J.M. Wouters, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Charlotte Zuur, Professor – Netherlands Cancer Institute - Antoni van Leeuwenhoek
Author: Willem Klop, MD PhD – Netherlands Cancer Institute - Antoni van Leeuwenhoek
Author: Jos van der Hage, Professor – Leiden University Medical Center
Author: Arjen J. Witkamp, MD PhD – UMC Utrecht
Author: Bart van der Wiel, MD PhD – Netherlands Cancer Institute - Antoni van Leeuwenhoek
Author: Robyn Saw, MBBS, FRACS, MS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Thomas Pennington, MBBS, FRACS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Kerwin Shannon, MBBS, FRACS – Melanoma Institute Australia
Author: Andrew Spillane, MBBS, MD, FRACS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Richard Scolyer, BMedSci MBBS MD FRCPA FRCPath(UK) FAHMS – Melanoma Institute Australia
Author: Georgina V. Long, MBBS PhD – Melanoma Institute Australia
Author: Christian Blank, MD PhD – Netherlands Cancer Institute - Antoni van Leeuwenhoek
Author: Alexander C.J van Akkooi, MD, PhD (he/him/his) – Melanoma Institute Australia / University of Sydney, Faculty of Medicine and Health / Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology
Melanoma
Friday, Mar 22nd
2:45pm - 3:05pm ET
Industry Spotlight Presented by Replimune: The Role of Oncolytic Immunotherapy in Oncology: Focus on Melanoma
Location: SSO HUB Theater
HUB Presenter: Giuseppe Gullo, MD – Replimune
Melanomanon-CMEHUB
Friday, Mar 22nd
3:15pm - 3:45pm ET
Controversies in Non-melanoma Skin Cancers
Location: SSO HUB: Breast & Endocrine Zone
HUB Moderator: Tawnya L. Bowles, MD (she/her/hers) – Intermountain Health
Melanomanon-CMEHUB
Friday, Mar 22nd
4:00pm - 5:00pm ET
Unanswered Questions in Melanoma in 2023
Location: Georgia Ballroom
Moderator: Christina V. Angeles, MD (she/her/hers) – Department of Surgery, Rogel Cancer Center, University of Michigan
Moderator: Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
MelanomaCME
Saturday, Mar 23rd
10:30am - 11:00am ET
Meet the Expert: Impactful and Practice Changing Trials in Melanoma Management
Location: C110
Expert: Vernon K. Sondak, MD (he/him/his) – H. Lee Moffitt Cancer Center and Research Institute
Breakout Moderator: Luke D. Rothermel, MD MPH – University Hospitals Cleveland Medical Center
MelanomaMeet the Expertsnon-CME